{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:09:04Z","timestamp":1777493344995,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Little is known about risperidone metabolism in a clinical sample, where polypharmacy is common. Such knowledge is important since several of its side effects are dose dependent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Medically healthy patients aged 7 to 17 years old treated with risperidone for at least 6 months were enrolled. Trough serum risperidone and 9-hydroxyrisperidone concentrations were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred seven participants (92% males) were recruited, representing a heterogenous clinical group with attention-deficit\/hyperactivity disorder, disruptive behavior disorders, pervasive developmental disorders, anxiety disorders, mood disorders, tic disorders, or psychotic disorders. Risperidone had been used at a mean dose of 0.03\u2009mg\/kg, for a mean 2.5 years, predominantly to treat irritability and aggression. Cytochrome CYP2D6 inhibitors were divided into prominent (fluoxetine, bupropion, and lamotrigine), intermediate (sertraline), and weak inhibition groups (citalopram or escitalopram). The concentrations of risperidone and its metabolite were strongly associated with the dose of risperidone and time since the last dose and, to a lesser extent, with male sex. In addition, risperidone concentration increased with pubertal stage (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05), while body mass index\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -score (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001) predicted a higher 9-hydroxyrisperidone concentration. The use of CYP2D6 inhibitors was much more strongly associated with risperidone concentration (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) than with its metabolite's (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In chronically treated youths, the metabolism of risperidone depends on the stage of sexual development, whereas that of 9-hydroxyrisperidone varies with body fat. Moreover, CYP2D6 inhibitors more strongly affect risperidone metabolism than that of its metabolite. The clinical implications of these findings, in relation to efficacy and tolerability, deserve further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2010.0038","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T19:30:56Z","timestamp":1302636656000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["Predictors of Risperidone and 9-Hydroxyrisperidone Serum Concentration in Children and Adolescents"],"prefix":"10.1177","volume":"21","author":[{"given":"Chadi Albert","family":"Calarge","sequence":"first","affiliation":[{"name":"The University of Iowa Carver College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Del D.","family":"Miller","sequence":"additional","affiliation":[{"name":"The University of Iowa Carver College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,4,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0045"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004000108"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/1044546041649020"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.8.1337"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.026"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979308"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1973.tb09943.x"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100101"},{"key":"e_1_3_3_10_1","volume-title":"Boehringer-Ingelheim: Prescribing Information for Catapres","year":"2006","unstructured":"Boehringer-Ingelheim: Prescribing Information for Catapres. Ridgefield, CT: BIP Inc., 2006."},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.3.2.229"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.007"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328329a60f"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04595gre"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(94)90174-0"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0103"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200202000-00006"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.68"},{"key":"e_1_3_3_20_1","volume-title":"Risperdal","author":"FDA","year":"2006","unstructured":"FDA. FDA Approves the First Drug to Treat Irritability Associated with Autism. Risperdal. Silver Spring, MD: FDA, 2006."},{"key":"e_1_3_3_21_1","volume-title":"Drug Approved for Two Psychiatric Conditions in Children and Adolescents","author":"FDA","year":"2007","unstructured":"FDA. Drug Approved for Two Psychiatric Conditions in Children and Adolescents. Silver Spring, MD: FDA, 2007."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.125783"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100033"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2001.01328.x"},{"key":"e_1_3_3_25_1","first-page":"13","article-title":"The pharmacokinetics of risperidone in humans: A summary","volume":"55","author":"Heykants J","year":"1994","unstructured":"Heykants J, , Huang ML, , Mannens G, , Meuldermans W, , Snoeck E, , Van Beijsterveldt L, , Van Peer A, , Woestenborghs R. The pharmacokinetics of risperidone in humans: A summary. J Clin Psychiatry, 55,Suppl:13\u201317. 1994.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.02.005"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.146"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100327"},{"key":"e_1_3_3_29_1","first-page":"25","volume-title":"Pediatric Nephrology","author":"Kon V","year":"2004","unstructured":"Kon V, , Ichikawa I. Glomerular circulation, function. Pediatric Nephrology. Avner E.D., , Harmon W.E., , Niaudet P. Philadelphia, PA: Lippincott Williams & Wilkins, 2004; 25\u201344."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00010"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.44.235.291"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.45.239.13"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.45"},{"key":"e_1_3_3_34_1","unstructured":"Ortho-McNeil-Janssen Pharmaceuticals I: Invega (paliperidone) Extended-Release Tablets: US Prescribing Information [online] 2007. http:\/\/www.invega.com\/invega\/shared\/pi\/invega.pdf."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000215326.51175.eb"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.09.026"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.3.438"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316870-000000000-00000"},{"key":"e_1_3_3_39_1","volume-title":"Prescribing Information for Daytrana","year":"2009","unstructured":"Shire. Prescribing Information for Daytrana. Wayne, PA: SU Inc., 2009a."},{"key":"e_1_3_3_40_1","volume-title":"Prescribing Information for Intuniv","year":"2009","unstructured":"Shire. Prescribing Information for Intuniv. Wayne, PA: SU Inc., 2009b."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021873"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245444"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0209-y"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318030-000000000-00000"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301181"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0212"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2010.0038","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2010.0038","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2010.0038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:54:59Z","timestamp":1777388099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2010.0038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1089\/cap.2010.0038"],"URL":"https:\/\/doi.org\/10.1089\/cap.2010.0038","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}